Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of “Buy” by Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have received a consensus rating of “Buy” from the nine brokerages that are covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $22.14.

ZVRA has been the topic of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a research report on Thursday. Canaccord Genuity Group boosted their price target on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday. Finally, Guggenheim boosted their price target on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday.

Insider Activity

In other news, EVP Joshua Schafer sold 10,500 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $82,530.00. Following the sale, the executive vice president now directly owns 29,486 shares of the company’s stock, valued at approximately $231,759.96. This represents a 26.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO R. Laduane Clifton sold 11,000 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the completion of the transaction, the chief financial officer now owns 51,361 shares in the company, valued at approximately $403,697.46. This trade represents a 17.64 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. MetLife Investment Management LLC grew its stake in Zevra Therapeutics by 8.1% in the 3rd quarter. MetLife Investment Management LLC now owns 22,866 shares of the company’s stock valued at $159,000 after buying an additional 1,717 shares during the last quarter. IFG Advisors LLC grew its stake in Zevra Therapeutics by 10.0% in the 4th quarter. IFG Advisors LLC now owns 29,050 shares of the company’s stock valued at $242,000 after buying an additional 2,650 shares during the last quarter. Invesco Ltd. grew its stake in Zevra Therapeutics by 19.6% in the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company’s stock valued at $153,000 after buying an additional 3,007 shares during the last quarter. Corebridge Financial Inc. grew its stake in Zevra Therapeutics by 16.9% in the 4th quarter. Corebridge Financial Inc. now owns 26,294 shares of the company’s stock valued at $219,000 after buying an additional 3,801 shares during the last quarter. Finally, Squarepoint Ops LLC grew its stake in Zevra Therapeutics by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock valued at $138,000 after buying an additional 4,384 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Trading Up 4.7 %

ZVRA opened at $8.31 on Wednesday. The stock has a market capitalization of $449.70 million, a P/E ratio of -4.22 and a beta of 1.98. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The firm’s fifty day simple moving average is $7.93 and its 200 day simple moving average is $8.16. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The company had revenue of $12.00 million during the quarter, compared to the consensus estimate of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. As a group, research analysts anticipate that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.